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Abstract: Primary Sjögren’s syndrome (pSjS) is a chronic systemic autoimmune disorder, primarily
affecting exocrine glands; its pathogenesis is still unclear. Long non-coding RNAs (lncRNAs) are
thought to play a role in the pathogenesis of autoimmune diseases and a comprehensive analysis of
lncRNAs expression in pSjS is still lacking. To this aim, the expression of more than 540,000 human
transcripts, including those ascribed to more than 50,000 lncRNAs is profiled at the same time, in
a cohort of 16 peripheral blood mononuclear cells PBMCs samples (eight pSjS and eight healthy
subjects). A complex network analysis is carried out on the global set of molecular interactions
among modulated genes and lncRNAs, leading to the identification of reliable lncRNA-miRNA-gene
functional interactions. Taking this approach, a few lncRNAs are identified as targeting highly
connected genes in the pSjS transcriptome, since they have a major impact on gene modulation in
the disease. Such genes are involved in biological processes and molecular pathways crucial in the
pathogenesis of pSjS, including immune response, B cell development and function, inflammation,
apoptosis, type I and gamma interferon, epithelial cell adhesion and polarization. The identification
of deregulated lncRNAs that modulate genes involved in the typical features of the disease provides
insight in disease pathogenesis and opens avenues for the design of novel therapeutic strategies.
Keywords: primary Sjögren’s syndrome; long non-coding RNA; signaling pathway; protein–protein
(PPI) network; gene module
1. Introduction
Sjögren’s syndrome (SjS) is a chronic systemic autoimmune disease of still unknown origin, that
may be present either alone (defined as primary SjS: pSjS) or associated with other autoimmune
diseases (defined as secondary SjS). The prevalence of pSjS in the general population is between 0.01
and 0.1% with a higher prevalence of the disease in women [1,2]. The clinical symptoms of pSjS include
exocrinopathy, resulting in dry eyes and mouth and extraglandular systemic manifestations such as
arthralgias, fatigue, vasculitis, pulmonary fibrosis and pulmonary hypertension, interstitial nephritis
and central and peripheral involvement of the nervous system [3].
Although little is known on the pathogenesis of the disease, several factors have been shown to
contribute to its onset, such as genetic background, environmental factors including viral infections [4]
and epigenetic mechanisms, such as microRNAs (miRNAs).
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Our attention is focused on the epigenetic mechanisms that may be involved in pSjS pathogenesis,
through the analysis of the modulation of long non-coding RNAs (lncRNAs) expression in pSjS patients.
The identification of lncRNAs modulated in the disease and an integrated analysis of lncRNAs,
miRNAs and gene expression profiles in patients affected by pSjS are reported here as an historical
first, to the best of the authors’ knowledge. Interestingly, the identified lncRNAs are able to modulate
pathogenetically relevant molecular pathways of the disease.
2. Materials and Methods
2.1. Patients
Eight female patients (mean age 52 ± 15 years old) affected by pSjS, attending the Unit of
Autoimmune Diseases at the University Hospital of Verona, Northern Italy, and 8 sex and age matched
healthy controls were enrolled. Both patients and controls were subjects of Caucasian origin from
Northern Italy. All patients enrolled in this study were diagnosed according to the American College
of Rheumatology (ACR)–European League against Rheumatism (EULAR) criteria [5]. They underwent
labial salivary gland biopsy and disease activity was evaluated at the moment of enrollment in
the study.
A written informed consent was obtained from all the participants of the study and the study
protocol was approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrata
di Verona (identification code 1538, version 3, date of approval 12 March 2012). All the investigations
have been performed according to the principles contained in the Helsinki declaration.
2.2. Microarray Analysis
Blood sample collection was carried out using BD Vacutainer K2EDTA tubes (Becton Dickinson,
Franklin Lakes, NJ, USA) and 21-gauge needles.
PBMCs isolation was performed by Ficoll–HyPaque (Pharmacia Biotech, Piscataway, NJ, USA)
gradient centrifugation. Patients and controls had similar PBMCs distribution. Total RNA was
extracted from PBMCs (107 cells) using an miRNeasy mini kit (Qiagen GmbH, Hilden, Germany).
cRNA preparation, samples hybridization and scanning were performed following the Affymetrix
(Affymetrix, Santa Clara, CA, USA) provided protocols using a Cogentech Affymetrix microarray unit
(Campus IFOM IEO, Milan, Italy). All samples were hybridized on a Human Clariom D (Thermo Fisher
Scientific, Waltham, MA, USA) gene chip. Signal intensities were analysed with the Transcriptome
Analysis Console (TAC) 4.0 software (Applied Biosystem, Foster City, CA, USA by Thermo Fisher
Scientific, Waltham, MA, USA).
Using the Human Clariom D arrays, more than 540,000 human transcripts were interrogated,
starting from as little as 100 pg of total RNA. Signal intensity was background-adjusted, normalized,
and log-transformed using the Signal Space Transformation (SST)-Robust Multi-Array Average
algorithm (RMA).
Differentially expressed genes that showed an expression level at least 1.5 fold different in the
test sample versus control sample at a significant level (p ≤ 0.01) were chosen for final consideration.
p-values were calculated applying the unpaired t-test and Bonferroni multiple testing correction.
Target annotations of long non-coding RNAs were retrieved using starBase v2.0 (http://starbase.
sysu.edu.cn/) where lncRNAs interactions, experimentally validated by high-throughput experimental
technologies, are registered [6].
The list of gene targets of microRNAs (miRNAs) that were targeted by lncRNAs were inferred
interrogating the FunRich database (www.funrich.org/) [7].
2.3. Protein–Protein Interaction (PPI) Network Construction and Network Clustering
The PPI network was constructed upon the experimentally validated protein–protein interactions
using STRING (Search Tool for the Retrieval of Interacting Genes) version 10.5 (http://string-db.org/) [8].
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Network topological analysis was performed using the Cytoscape software (version 3.7, (www.
cytoscape.org) [9].
High-flow areas (highly connected regions) of the network (modules) were detected using the
MCODE plugin of Cytoscape (k-core = 4 and node score cutoff = 0.2).
2.4. Gene Functional Classification and Enrichment Analysis
Genes were classified functionally into Biological Processes (BPs) according to the Gene
Ontology (GO) project annotations (www.geneontology.org) by the Panther expression analysis tools
(http://pantherdb.org/) [10].
Pathway classification and enrichment (hypergeometric p-value ≤ 0.05) analysis were achieved
with FunRich.
2.5. Real Time PCR of lncRNAs
Five hundred ng of total RNA was treated with 1 unit of DNase I Amplification Grade (Invitrogen;
Carlsbad, CA, USA). First-strand cDNA was generated using the SuperScript IV First-Strand Synthesis
System (Invitrogen; Carlsbad, CA, USA) with random hexamers, according to the manufacturer’s
protocol. Real time PCR was performed in triplicate with PowerUp™ Sybr® Green reagent (Applied
Biosystems; Foster City, CA, USA) in a QuantStudio 6 Flex system (Applied Biosystems; Foster City, CA,
USA). Transcripts of relative expression levels were obtained after normalization against the geometric
mean of the housekeeping genes Glyceraldehyde 3-phosphate dehydrogenase GAPDH and beta-actin
(ACTB) expression. The ∆∆Ct method of relative quanrtification was used for comparing relative fold
expression differences. Results are expressed as fold changes with respect to healthy subjects.
2.6. Real Time PCR of Genes Modulated in pSjS Patients
First-strand cDNA was obtained using the SuperScript III First-Strand Synthesis System for
RT-PCR Kit (Invitrogen), with random hexamers, following the manufacturer’s protocol. PCR was
performed in a total volume of 25 µL containing 1× Taqman Universal PCR Master mix, no AmpErase
UNG and 2.5 µL of cDNA; pre-designed, gene-specific primers and probe sets for each gene were
obtained from Assay-on-Demande Gene Expression Products service (Applied Biosystems).
Real-Time PCR reactions were carried out in a two-tube system and in singleplex. The Real-
Timeamplifications encompassed 10 min at 95 ◦C (AmpliTaq Gold activation), followed by 40 cycles at
95 ◦C for 15 s and at 60 ◦C for one minute. Thermocycling and signal detection were performed with a
7500 Sequence Detector (Applied Biosystems). Signals were detected following the manufacturer’s
instructions. This methodology allowed the identification of the cycling point where the PCR product
was detectable by means of fluorescence emission (Threshold cycle or Ct value). The Ct value correlated
to the quantity of target mRNA. Relative expression levels were calculated for each sample after
normalization against the housekeeping genes GAPDH, beta-actin and 18 s ribosomal RNA (rRNA)
using the ∆∆Ct method for comparing relative fold expression differences. Ct values for each reaction
were determined using TaqMan SDS analysis software. Each amount of RNA tested had triplicate
Ct values averaged. Since Ct values varied linearly with the logarithm of the amount of RNA, this
average represented a geometric mean.
2.7. Real Time PCR of microRNAs
miRNAs expression was evaluated by TaqMan® Advanced miRNA assays chemistry (Applied
Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed and pre-amplified
with a TaqMan® Advanced miRNA cDNA synthesis kit according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA, USA). Pre-amplified cDNA was diluted 1/10 in nuclease-free
water and 5 µL of diluted cDNA for each replicate was loaded in PCR. Twenty µL PCR reactions were
composed by 2× Fast Advanced Master Mix and TaqMan® Advanced miRNA assays for miR-30e-5p,
miR-32-5p, miR-155-5p, miR-195-5p, miR-378a-3p and miR-30b-5p. The mean of Ct for hsa-miR-16-5p
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and hsa-miR-26a-5p expression was used to normalize miRNA expression. Real time PCR was carried
out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems, Foster City, CA, USA).
Expression values were reported as fold change with respect to healthy controls by ∆∆Ct method
employing QuantStudio Real-Time PCR system software v. 1.3.
3. Results
3.1. Patients Characteristics
All the patients enrolled in the study had antinuclear antibodies >1:640, nuclear dots or
homogeneous patterns, and were positive for anti-ENA antibodies SSA/Ro; four of them also were
positive for anti-SSB antibodies. Labial salivary gland histopathology showed a focal lymphocytic
sialadenitis with a focus score >1 [11]. The median Eular Sjogren’s syndrome disease activity index
(ESSDAI) score was 6. The median Eular Sjogren’s syndrome Patient Reported Index (ESSPRI) score
was 7 [12]. Three patients presented germinal centre-like structures in their labial salivary gland biopsy
and one patient developed a B cell lymphoma soon after enrollment in the study.
3.2. High-Throughput Gene and Long Non-Coding RNA Expression Profiling in Peripheral Blood Mononuclear
Cells of Patients with pSjS
Intending to identify lncRNAs potentially involved in pSjS pathogenesis, the expression of more
than 540,000 human transcripts, including those ascribed to more than 50,000 lncRNAs, was profiled
at the same time, in a cohort of 16 PBMCs samples (8 pSjS and 8 healthy subjects). Transcriptional
profiles of pSjS patients and healthy subjects were compared and, after a robust filtering procedure
(Bonferroni-corrected p-value ≤ 0.01 and fold change ≥ |1.5|), 2503 coding-genes were modulated
significantly (Table S1).
The functional classification by Gene Ontology (http://www.geneontology.org/) of the 2503
differentially expressed genes (DEGs) revealed that they were involved in meaningful biological
processes (BPs) known to play a role in the disease, including apoptosis, cell adhesion, immune response,
type I Interferon signaling, Interferon-gamma signaling, extracellular matrix (ECM) organization and
morphogenesis of a branching epithelium. A selection of genes that play a role in the above mentioned
BPs is shown in Table 1.
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Table 1. Selection of significant differentially expressed genes in pSjS patients versus healthy subjects, grouped according to the biological processes to which they
are ascribed.
Gene Symbol Description Fold Change p-Value mRNA Accession
Apoptosis
CCAR2 cell cycle and apoptosis regulator 2 1.83 0.002 NM_021174
CASP10 caspase 10 2.26 0.004 NM_001206524
BCL2L13 BCL2-like 13 (apoptosis facilitator) 2.49 <0.001 NM_001270726
BCL2L12 BCL2-like 12 (proline rich) 2.44 0.002 NM_001040668
PYCARD PYD and CARD domain containing 2.52 0.004 NM_013258
DAPK3 death-associated protein kinase 3 2.09 <0.001 NM_001348
PDCD6 programmed cell death 6 2.93 <0.001 NM_001267556
CASP9 caspase 9 2.01 <0.001 NM_001229
DEDD2 death effector domain containing 2 3.82 <0.001 NM_001270614
BMF Bcl2 modifying factor 1.88 0.003 NM_001003940
PDCD7 programmed cell death 7 1.98 0.001 NM_005707
FADD Fas (TNFRSF6)-associated via death domain 2.06 <0.001 NM_003824
ANP32B acidic nuclear phosphoprotein 32 family member B 2.34 <0.001 NM_006401
BRI3 brain protein I3 1.87 0.003 NM_001159491
CLPTM1L CLPTM1-like 2.8 <0.001 NM_030782
ING2 inhibitor of growth family member 2 1.97 <0.001 NM_001291959
BFAR bifunctional apoptosis regulator 1.98 0.003 NM_016561
DAP death-associated protein 2.42 0.004 NM_001291963
SORT1 sortilin 1 2.51 0.008 NM_001205228
RRAGA Ras-related GTP binding A 1.76 0.001 NM_006570
Cell adhesion
LIN7C lin-7 homolog C (C. elegans) −1.76 0.001 NM_018362
ITGB3BP integrin beta 3 binding protein (beta3-endonexin) −2.87 0.001 NM_001206739
PRKCE protein kinase C, epsilon −1.62 0.005 NM_005400
FER fer (fps/fes related) tyrosine kinase −2.3 0.001 NM_001308028
ADAM8 ADAM metallopeptidase domain 8 3.13 <0.001 NM_001109
ADAM15 ADAM metallopeptidase domain 15 3.59 <0.001 NM_001261464
CLDN5 claudin 5 1.69 0.007 NM_001130861
EMP2 epithelial membrane protein 2 1.71 0.005 NM_001424
ICAM3 intercellular adhesion molecule 3 2.86 <0.001 NM_002162
HN1 hematological and neurological expressed 1 2.71 <0.001 NM_001002032
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Table 1. Cont.
Gene Symbol Description Fold Change p-Value mRNA Accession
ITGA5 integrin alpha 5 2.22 <0.001 NM_002205
MISP mitotic spindle positioning 1.86 0.003 NM_173481
PTPRJ protein tyrosine phosphatase, receptor type, J 1.71 0.006 NM_001098503
RHOC ras homolog family member C 2.5 0.004 NM_001042678
ZEB1 zinc finger E-box binding homeobox 1 −4.18 <0.001 NM_001128128
ZFYVE21 zinc finger, FYVE domain containing 21 3.07 0.001 NM_001198953
Immune response
LAMTOR2 late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 3.08 0.002 NM_001145264
IL6R interleukin 6 receptor 1.79 0.001 NM_000565
IGKV3D-7 immunoglobulin kappa variable 3D-7 4.17 0.004 OTTHUMT00000476805
IGLV3-19 immunoglobulin lambda variable 3-19 6.58 0.002 OTTHUMT00000321830
HLA-G major histocompatibility complex, class I, G 2.98 <0.001 NM_002127
NCF1 neutrophil cytosolic factor 1 2.17 0.003 NM_000265
CD68 CD68 molecule 2.18 0.002 NM_001040059
DEF6 DEF6 guanine nucleotide exchange factor 1.58 0.003 NM_022047
LILRA6 leukocyte immunoglobulin-like receptor, subfamily A, member 6 2.37 0.004 NM_024318
TRBV24-1 T cell receptor beta variable 24-1 3.57 0.001 OTTHUMT00000352499
IL5RA interleukin 5 receptor, alpha 2.14 <0.001 NM_000564
CD6 CD6 molecule 3.71 <0.001 NM_001254750
CD7 CD7 molecule 1.93 <0.001 NM_006137
BTK Bruton agammaglobulinemia tyrosine kinase 1.79 0.006 NM_000061
BAX BCL2-associated X protein 3.14 <0.001 NM_001291428
BAK1 BCL2-antagonist/killer 1 2.46 0.005 NM_001188
GATA3 GATA binding protein 3 1.74 0.008 NM_001002295
TAP1 antigen peptide transporter 1 2.58 <0.001 NM_001292022
TAP2 antigen peptide transporter 2 2.23 0.002 NM_018833
IL17RA interleukin 17 receptor A 2.52 0.001 NM_001289905
IL23A interleukin 23, alpha subunit p19 −2.9 0.009 NM_016584
IL4R interleukin 4 receptor 2.37 <0.001 NM_000418
CD33 CD33 molecule 3.39 0.002 NM_001082618
IL2RA interleukin 2 receptor, alpha 1.89 0.006 NM_000417
LAT linker for activation of T-cells 3.25 <0.001 NM_001014987
C1RL complement component 1, r subcomponent-like 1.52 0.010 NM_001297640
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 3.2 <0.001 NM_000566
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Table 1. Cont.
Gene Symbol Description Fold Change p-Value mRNA Accession
CD81 CD81 molecule 2.04 0.008 NM_001297649
KLHL20 kelch-like family member 20 −1.94 0.004 NM_014458
KLHL6 kelch-like family member 6 2.18 0.005 NM_130446
ORAI1 ORAI calcium release-activated calcium modulator 1 2.97 <0.001 NM_032790
CBX8 chromobox homolog 8 1.62 0.008 NM_020649
ENO1 enolase 1, (alpha) 1.91 0.004 NM_001201483
GNAI2 guanine nucleotide binding protein, alpha inhibiting activity polypeptide2 1.67 0.007 NM_001166425
SPI1 Spi-1 proto-oncogene 1.73 0.007 NM_001080547
TRAF3 TNF receptor-associated factor 3 −1.63 0.009 NM_001199427
HNRNPL heterogeneous nuclear ribonucleoprotein L 2.16 0.001 NM_001005335
FOSL1 FOS-like antigen 1 −2.14 0.008 NM_001300844
Type I interferon signaling
IRF5 interferon regulatory factor 5 2.24 0.003 NM_001098627
IRF7 interferon regulatory factor 7 3.14 0.002 NM_001572
IRF9 interferon regulatory factor 9 2.68 <0.001 NM_006084
MYD88 myeloid differentiation primary response 88 1.86 0.005 NM_001172566
HLA-H major histocompatibility complex, class I, H (pseudogene) 2.18 0.004 NR_001434
OAS1 2-5-oligoadenylate synthetase 1 3.58 0.002 NM_001032409
IFI35 interferon-induced protein 35 1.78 0.007 NM_005533
IFITM3 interferon induced transmembrane protein 3 2.54 0.006 NM_021034
IFNA10 interferon, alpha 10 1.99 0.002 NM_002171
ADAR adenosine deaminase, RNA-specific 3.15 0.005 NM_001025107
OAS3 2-5-oligoadenylate synthetase 3 4.27 0.008 NM_006187
STAT1 signal transducer and activator of transcription 1 1.75 0.008 NM_007315
KLHL20 kelch-like family member 20 −1.94 0.004 NM_014458
Interferon-gamma signaling
HLA-G major histocompatibility complex, class I, G 2.98 <0.001 NM_002127
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 2.25 0.002 NM_001004340
PML promyelocytic leukemia 3.18 0.002 NM_002675
STAT1 signal transducer and activator of transcription 1 1.75 0.008 NM_007315
TRIM21 tripartite motif containing 21 2.13 0.002 NM_003141
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 3.2 <0.001 NM_000566
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Table 1. Cont.
Gene Symbol Description Fold Change p-Value mRNA Accession
Inflammatory response
CCR4 chemokine (C-C motif) receptor 4 3.73 0.005 NM_005508
CCR8 chemokine (C-C motif) receptor 8 2.24 0.004 NM_005201
IL6R interleukin 6 receptor 1.79 0.001 NM_000565
MYD88 myeloid differentiation primary response 88 1.86 0.005 NM_001172566
CSF1 colony stimulating factor 1 (macrophage) 2.23 0.005 NM_000757
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 2.48 <0.001 NM_002415
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 4.39 <0.001 NM_001065
TGFB1 transforming growth factor beta 1 1.71 0.003 NM_000660
LTB4R leukotriene B4 receptor 2.46 <0.001 NM_001143919
ALOX5 arachidonate 5-lipoxygenase 2.57 0.007 NM_000698
IL23A interleukin 23, alpha subunit p19 −2.9 0.009 NM_016584
CXCR3 chemokine (C-X-C motif) receptor 3 2.25 0.002 NM_001142797
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) 2.48 <0.001 NM_002415
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 1.94 0.007 NM_005195
MAP3K12 mitogen-activated protein kinase kinase kinase 12 1.88 0.005 NM_001193511
TRIB2 tribbles pseudokinase 2 2.19 0.005 NM_021643
ECM organization
MMP9 matrix metallopeptidase 9 3.31 0.002 NM_004994
EFEMP2 EGF containing fibulin-like extracellular matrix protein 2 2.43 0.001 NM_016938
ADAM15 ADAM metallopeptidase domain 15 3.59 <0.001 NM_001261464
ADAM8 ADAM metallopeptidase domain 8 3.13 <0.001 NM_001109
BSG basigin (Ok blood group) 2.07 0.001 NM_001728
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) 1.57 0.003 NM_001165928
CTGF connective tissue growth factor 1.54 0.006 NM_001901
TGFB1 transforming growth factor beta 1 1.71 0.003 NM_000660
LOXL3 lysyl oxidase-like 3 2.02 0.002 NM_001289164
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 2.2 0.006 NM_001134434
Morphogenesis of a branching epithelium
CTSZ cathepsin Z 2.99 0.002 NM_001336
ILK integrin linked kinase 1.82 0.001 NM_001014794
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) 1.57 0.003 NM_001165928
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Table 1. Cont.
Gene Symbol Description Fold Change p-Value mRNA Accession
EDN1 endothelin 1 −2.17 0.002 NM_001168319
TGFB1 transforming growth factor beta 1 1.71 0.003 NM_000660
GREM1 gremlin 1 1.53 0.009 ENST00000633992
ENG endoglin 2.42 <0.001 NM_000118
Epithelial cells polarization
ARF6 ADP-ribosylation factor 6 1.53 0.008 NM_001663
FRMD4A FERM domain containing 4A 1.85 0.003 NM_018027
RHOQ ras homolog family member Q 1.79 0.005 NM_012249
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LncRNA profiling showed a statistically significant variation (Bonferroni-corrected p-value ≤ 0.01
and fold change ≥ |1.5|) for 199 long non-coding RNAs (Table S2).
Since modulated genes are well representative of BPs and pathways strictly connected to the
disease, we decided to verify whether the modulated lncRNAs could be connected functionally to the
pSjS transcriptome, thus playing a role in pSjS pathophysiology.
The identified 199 lncRNAs were then analysed, retaining only those transcripts for which
experimentally validated microRNA (miRNA) targets had already been annotated in starBase and,
among these, only lncRNAs that targeted at least 10 miRNAs were selected.
Using this approach, we obtained 6 lncRNAs, including CTD-2020K17.1, LINC00657,
RP11-169K16.9, LINC00511, RP11-372K14.2 and RP11-214O1.2. (Table 2).
To strengthen the significance of our analysis we wanted to verify the ability of the selected
lncRNAs to regulate genes that are differentially expressed in pSjS samples through the interaction with
their miRNA targets. We therefore evaluated the entire lists of their miRNA targets that were validated
experimentally by high-throughput technologies and selected only those miRNAs that targeted genes
modulated in pSjS patients to bona fide outline authentic interactions that are well established in pSjS.
Shown in Table 2, LINC00657, LINC00511 and CTD-2020K17.1 targeted the highest number of
modulated genes (Table S3). The expression data were confirmed by RT-PCR (Figure S1).
Table 2. Selected long non-coding RNAs modulated in pSjS patients versus healthy subjects.
Gene Symbol Description Fold Change p-Value Public Gene IDs
LINC00657 long intergenic non-proteincoding RNA 657 1.8 0.001 NR_027451
LINC00511 long intergenic non-proteincoding RNA 511 −2.0 0.008 NR_036488
CTD-2020K17.1 novel transcript, antisense toFMNL1 2.7 0.000 ENST00000585471.1
RP11-169K16.9 uncharacterized LOC729614 1.7 0.008 NR_024279
RP11-214O1.2 uncharacterized proteinMGC12916 −2.1 0.010 NR_026880
RP11-372K14.2 novel transcript, antisense toSH3D19 −2.1 0.004 ENST00000603472.1
Gene Symbol miRNA Targets
Total Number of
Targeted
Modulated Genes
Targeted Modules
Total Number of Targeted
Module-Associated
Genes
LINC00657 67 313 7 75
LINC00511 11 194 7 41
CTD-2020K17.1 11 120 7 25
RP11-169K16.9 13 90 5 15
RP11-214O1.2 12 86 4 13
RP11-372K14.2 12 75 4 12
3.3. PPI Network and Modular Analysis of Genes and lncRNAs Modulated in pSjS
Since the modulation of highly connected genes can have a more pronounced effect in the disease
pathogenesis than the modulation of genes that are not functionally connected, we evaluated whether
the 6 selected lncRNAs could target highly interacting genes in pSjS.
Considering this, to prioritize transcripts that may have a role in the pSjS pathogenesis, we
performed a network analysis dissecting all the differentially expressed genes in pSjS that were
connected functionally. We therefore constructed a protein–protein interaction (PPI) network that
included all the experimentally validated functional interactions among the protein products of the
2503 modulated genes in pSjS (Figure 1A). The obtained network included 2500 modulated genes
(nodes) that were connected by 14,169 pairs of interactions (edges) and showed a good PPI enrichment
p-value (<10−16).
Moreover, since genes that are strictly connected to the disease phenotype display a strong
tendency to cluster together in few network regions [13], we performed a modular analysis to find
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areas in which the most highly connected genes were clustered. Using this approach, we could identify
7 gene modules that are most likely to be involved in the disease pathogenesis (Figure 1B and Table S4).
All 7 modules were imported in Cytoscape adding to their scaffolds miRNAs-genes, and
lncRNAs—miRNAs interactions.
The topological analysis of such implemented modules highlighted, for the 6 lncRNAs, the
lncRNA–gene interactions mediated by their targeted miRNAs. We observed that LINC00657,
LINC00511 and CTD-2020K17.1 targeted highly connected genes and the highest number of
module-associated genes that were distributed in all the 7 modules (Table 2 and Table S5).
We therefore narrowed our analysis to CTD-2020K17.1, LINC00511, and LINC00657 lncRNAs,
since they most probably had a major impact on pSjS transcriptome (as also suggested by the network
analysis), (Figure 2).
Noteworthy, targeted genes included several important transcripts involved in T cell development
(GATA3), in the response to type I interferon (IRF5, IRF9 and KLHL20), in inflammatory response (IL6R
and CEBPD) and in B-cell physiology and malignancy (BAK1, BAX, CBX8, ENO1, GNAI2, HNRNPL,
LTBR, TRAF3 and WDR5).
When we analysed the list of miRNAs regulated by the 3 lncRNAs (Table S6), we found that 6
miRNAs played a role in B cell development, for example mir-17-5p, mir-20b-5p, mir-34a-5p, mir-34c-5p,
mir-155-5p and mir-93-5p [14,15], and that 51 miRNAs have been previously associated with several
types of human B cell lymphomas. Noteworthy, 15 of the above mentioned miRNAs were already
associated to pSjS (see Table 3).
Table 3. miRNA targets of the selected lncRNAs that have been associated to lymphoma and/or pSjS.
MiRNAs Previously Associated to Lymphoma
lncRNA miRNA Target References
LINC00657 hsa-miR-106a-5p Diffuse large B cell lymphoma [16]
LINC00657 hsa-miR-106b-5p Diffuse large B cell lymphoma [16]
LINC00657 hsa-miR-144-3p Diffuse large B cell lymphoma [17]
LINC00657 hsa-miR-155-5p Diffuse large B cell lymphoma [18]
LINC00511 hsa-miR-15a-5p Diffuse large B cell lymphoma [19]
LINC00511 hsa-miR-15b-5p Mantle cell lymphoma [20]
LINC00511 hsa-miR-16-5p Diffuse large B cell lymphoma [21]
LINC00657 hsa-miR-17-5p Burkitt’s lymphoma [22]
LINC00657 hsa-miR-182-5p Mantle cell lymphoma [22]
LINC00511 hsa-miR-183-5p Hodgkin’s lymphoma [23]
LINC00511 hsa-miR-195-5p Diffuse large B cell lymphoma [24]
CTD-2020K17.1 hsa-miR-199a-5p Mantle cell lymphoma [25]
CTD-2020K17.1 hsa-miR-199b-5p Diffuse large B cell lymphoma [26]
LINC00657 hsa-miR-20a-5p Diffuse large B cell lymphoma [16]
LINC00657 hsa-miR-20b-5p Mantle cell lymphoma [27]
LINC00657 hsa-miR-22-3p Diffuse large B cell lymphoma [28]
LINC00657 hsa-miR-26a-5p Burkitt’s lymphoma [29]
LINC00657 hsa-miR-26b-5p Burkitt’s lymphoma [29]
LINC00511 hsa-miR-29a-3p Mantle cell lymphoma [30]
LINC00511 hsa-miR-29b-3p Mantle cell lymphoma [30]
LINC00511 hsa-miR-29c-3p Mantle cell lymphoma [30]
LINC00657 hsa-miR-302a-3p Hodgkin Lymphoma [31]
LINC00657 hsa-miR-302b-3p Hodgkin’s Lymphoma [31]; diffuse large B cell lymphoma [32]
LINC00657 hsa-miR-302c-3p Hodgkin’s Lymphoma [31]; mantle cell lymphoma [27]
LINC00657 hsa-miR-30a-5p Non-Hodgkin’s B cell lymphoma [33]
LINC00657 hsa-miR-30b-5p Non-Hodgkin’s B cell lymphoma [33]
LINC00657 hsa-miR-30c-5p Non-Hodgkin’s B cell lymphoma [33]
LINC00657 hsa-miR-30d-5p Non-Hodgkin’s B cell lymphoma [33]
LINC00657 hsa-miR-30e-5p Non-Hodgkin’s B cell lymphoma [33]
CTD-2020K17.1 hsa-miR-34a-5p Diffuse large B cell lymphoma [34]
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Table 3. Cont.
MiRNAs Previously Associated to Lymphoma
lncRNA miRNA Target References
LINC00657 hsa-miR-363-3p Mantle cell lymphoma [22]
LINC00657 hsa-miR-372-3p Mantle cell lymphoma [27]
LINC00657 hsa-miR-373-3p Mantle cell lymphoma [27]
LINC00657 hsa-miR-378a-3p Hodgkin’s lymphoma [35]
LINC00657 hsa-miR-378b Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-378c Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-378d Mantle cell lymphoma [37]; Epstein–Barr virus-associated B-celllymphoma [36]
LINC00657 hsa-miR-378e Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-378f Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-378h Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-378i Epstein–Barr virus-associated B-cell lymphoma [36]
LINC00657 hsa-miR-421 Diffuse large B cell lymphoma [32]
LINC00657 hsa-miR-422a Burkitt’s lymphoma [38]
LINC00511 hsa-miR-424-5p Diffuse large B cell lymphoma [39]
LINC00511 hsa-miR-497-5p Diffuse large B cell lymphoma [24]
LINC00657 hsa-miR-519d-3p Diffuse large B cell lymphoma [32]
LINC00657 hsa-miR-520a-3p Hodgkin’s Lymphoma [30]
LINC00657 hsa-miR-520c-3p Diffuse large B cell lymphoma [40]
LINC00657 hsa-miR-520d-3p Diffuse large B cell lymphoma [41]
LINC00657 hsa-miR-92a-3p Diffuse large B cell lymphoma [42]; Non-Hodgkin’s B celllymphoma [22]
LINC00657 hsa-miR-92b-3p Mantle cell lymphoma [22]
MiRNAs Previously Associated to pSjS
lncRNA miRNA target References
LINC00657 hsa-miR-106a-5p [43]
LINC00657 hsa-miR-155-5p [44]
LINC00511 hsa-miR-15a-5p [43]
LINC00511 hsa-miR-16-5p [43]
LINC00657 hsa-miR-17-5p [43]
LINC00511 hsa-miR-183-5p [45]
LINC00511 hsa-miR-195-5p [46]
LINC00657 hsa-miR-20a-5p [43]
LINC00657 hsa-miR-20b-5p [43]
LINC00657 hsa-miR-26a-5p [43]
LINC00657 hsa-miR-30b-5p [46]
LINC00657 hsa-miR-30c-5p [46]
LINC00657 hsa-miR-32-5p [46]
CTD-2020K17.1 hsa-miR-34a-5p [43]
LINC00657 hsa-miR-378a-3p [43,46]
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3.4. Functional Analysis of Modulated Genes Targeted in the Whole Transcriptome
Once we identified the three lncRNAs that most likely exert a major impact on the whole
transcriptome, we wanted to verify if these transcripts could regulate genes that may play a crucial
role in the disease.
The three lncRNAs targeted genes involved in several meaningful biological processes. Indeed,
LINC00657 regulated a large number of genes involved in cell adhesion including HN1 (F.C. +2.71),
ITGA5 (F.C. +2.22), MISP (F.C. +1.86), PRKCE (F.C. −1.62), PTPRJ (F.C. +1.71), RHOC (F.C. +2.5), ZEB1
(F.C. −4.18) and ZFYVE21 (F.C. +3.07) as well as several transcripts that play a role in epithelial cell
polarization such as ARF6 (F.C. +1.53), FRMD4A (F.C. +1.859) and RHOQ (F.C. +1.79). Additionally,
many genes implicated in apoptosis also were targeted by LINC00657, including ANP32B (F.C. +2.34),
BCL2L12 and BCL2L13 (F.C. +2.44 and +2.49 respectively), BMF (F.C. +1.88), BRI3 (F.C. +1.87),
CLPTM1L (F.C. +2.8) and ING2 (F.C. +1.97). We also observed that LINC00657 regulated genes
involved in T cell development (GATA3, F.C. +1.74) and in T cell activation (ORAI1, F.C. +2.97) as
well as genes related to B cell activity, i.e., CBX8 (F.C. +1.62), ENO1 (F.C. +1.91), GNAI2 (F.C. +1.67),
SPI1/PU.1 (F.C. +1.73) and TRAF3, a critical regulator of B cell homeostasis (F.C. −1.63). Finally,
LINC00657 targeted genes involved in the inflammatory response including CEBPD (F.C. +1.94),
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LTB4R (F.C. +2.46), MAP3K12 (F.C. +1.88) and (TRIB2 (F.C. +2.19) and in type I interferon signaling
such as IRF5 (F.C. +2.24), IRF9 (F.C. +2.68) and KLHL20 (F.C. −1.94).J. Clin. Med. 2019, 8, x FOR PEER REVIEW 14 of 27 
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Figure 2. Functional interactions among the three selected lncRNAs and genes modulated in pSjS
patients. Degree sorted circle layouts of the protein–protein interaction (PPI) network of differentially
expressed genes in pSjS patients are shown. Genes (nodes) are ordered around a circle based on their
degree of connectivity (number of edges).
LINC00511 regulated a large number of transcripts involved in apoptosis, including BMF (F.C.
+1.88), BFAR (F.C. 1.98), DAP (F.C. +2.42) PDCD6 (F.C. +2.93), SORT1 (F.C. +2.51) and RRAGA (F.C.
+1.76) whereas CTD-2020K17.1 predominantly targeted differentially expressed genes involved in
B cell functions including GNAI2 (F.C. +1.67) HNRNPL (F.C. +2.16) FOSL1/FRA1, the inhibitor of
follicular B cell differentiation into plasma cells (F.C. −2.14) and the previously mentioned TRAF3.
Moreover, CTD-2020K17.1 also regulated the BAK1 gene (F.C. +2.46) that is frequently overexpressed
in B cell lymphomas.
Since it is widely acknowledged that disease phenotypes reflect complex molecular interactions
and that human disorders should be considered in terms of perturbations of molecular interaction
networks [13], we next performed a pathway enrichment analysis of genes targeted by the three
selected lncRNAs.
Signaling pathways involved in apoptosis were enriched in genes targeted by the three lncRNAs
which included “Intrinsic Pathway for Apoptosis” (LINC00511, and LINC00657) and “Class I PI3K
signaling events mediated by Akt” (CTD-2020K17.1, LINC00511, and LINC00657) (Figure 3 and
Table S7).
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Figure 3. Meaningful pathways enriched in modulated genes targeted by the three selected lncRNAs.
Colored squares indicate pathways enriched in genes targeted by the three lncRNAs: CTD-2020K17.1
(green squares); LINC00657 (red squares); LINC00511 (blue squares). The modules with the same
enriched pathways are shown.
Several targeted pathways that play a role in cell-to-cell interactions in epithelial tissue were
enriched ncluding: “CDC42 signali g events” (LINC00511 an LINC00657); “E-cadherin signaling
events” (LINC00511 and LINC00657); “E-cadherin signaling in the nascent adherens junction”
(LINC00511 and LINC00657); “Integrin family cell surface interactions” (LINC00511 and LINC00657);
and “Nectin adhesion pathway” (CTD-2020K17.1, LINC00511 and LINC00657).
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Signaling pathways involved in cell proliferation also were enriched i.e., “Signaling events
mediated by focal adhesion kinase” (CTD-2020K17.1, LINC00511 and LINC00657) and “C-MYB
transcription factor network” (LINC00657). Moreover, pathways implicated in branching
morphogenesis were targeted including “Canonical Wnt signaling pathway” (LINC00511) and
“Proteoglycan syndecan-mediated signaling events” (CTD-2020K17.1, LINC00511 and LINC00657).
Interestingly, three pathways regulating salivary gland morphogenesis were targeted by the selected
lncRNAs and these encompassed “EGF receptor signaling pathway” (CTD-2020K17.1, LINC00511
and LINC00657), “Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)”
(CTD-2020K17.1, LINC00511 and LINC00657) and “BMP receptor signaling” (CTD-2020K17.1).
“TGF-beta receptor signaling”, a pathway that influences salivary gland physiology, and its downstream
pathway “SMAD signaling” were targeted by LINC00511 and LINC00657.
Several pathways ascribed to the immune response were enriched in modulated targeted genes
including “IFN-gamma pathway” (CTD-2020K17.1, LINC00511 and LINC00657), “CD4+ TCR pathway”
(CTD-2020K17.1, LINC00511 and LINC00657) and “Role of Calcineurin-dependent NFAT signaling
in lymphocytes” (LINC00511). Particularly, several pathways involved in B cell development and
activation were enriched including the previously mentioned “Class I PI3K signaling events mediated by
Akt” (CTD-2020K17.1, LINC00511, and LINC00657), “CXCR4-mediated signaling events” (LINC00511
and LINC00657), and the mTor signaling (CTD-2020K17.1, LINC00511 and LINC00657).
The three lncRNAs targeted several proinflammatory pathways such as “Interleukin-3”
(CTD-2020K17.1, LINC00511 and LINC00657), “Intreleukin-5” (CTD-2020K17.1, LINC00511
and LINC00657) and “Interleukin-8” (LINC00657) signaling, “p38 MAPK signaling pathway”
(CTD-2020K17.1), “GMCSF-mediated signaling events” (CTD-2020K17.1, LINC00511 and LINC00657),
“Sphingosine 1-phosphate (S1P) pathway” (CTD-2020K17.1, LINC00511 and LINC00657) “TNF
alpha/NF-kB” (LINC00657) and the above cited “IFN-gamma pathway” (Figure 3).
3.5. Functional Analysis of Highly Connected Genes that are Included in Modules
Since genes that show the highest number of interactions in the transcriptome most likely are
involved in the disease pathogenesis, we next performed a functional analysis of the seven identified
gene modules.
Figure 4 summarizes genes targeted in the 7 modules and their respective targeting miRNAs
along the most relevant enriched signaling pathways.
M1 included 66 genes and was globally targeted by 29 miRNAs. The top enriched (p ≤ 0.05)
pathways in Module M1 were those involved in mRNA processing, including mRNA splicing (Table S8).
M2, included 123 genes and was targeted by 49 miRNAs. Aside from pathways related to cell
division (i.e., “DNA Replication”, “Cell Cycle, Mitotic” and “Mitotic M-M/G1 phases”) and energy
metabolism (i.e., “Respiratory electron transport”) other meaningful pathways were enriched in
this module, including signaling of Interferon alpha/beta and gamma, “Antigen processing-Cross
presentation”, “Regulation of Apoptosis”, “Signaling by Wnt” and “TNF alpha/NF-kB” signaling.
M3 included 108 genes and was targeted by 45 miRNAs. “Interferon gamma”, “Interferon
alpha/beta”, “Antigen Presentation: Folding, assembly and peptide loading of class I MHC”, “mTOR
signaling pathway”, “Class I PI3K signaling events mediated by Akt”, “EGF receptor (ErbB1) signaling
pathway” and “GMCSF-mediated signaling events” were among the most relevant enriched pathways
in Module M3.
M4 included 101 genes and was the most targeted module, indeed 64 miRNAs were found to
be linked to it. This module mostly was enriched in pathways involved in cell metabolism and in
other important pathways including “Extrinsic Pathway for Apoptosis”, “IL8-mediated signaling
events”, “TNF receptor signaling pathway”, “p38 MAPK signaling pathway” and “CXCR4-mediated
signaling events”.
J. Clin. Med. 2019, 8, 1349 17 of 27
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 17 of 27 
 
 
Figure 4. Pathways enrichment of modulated genes included in the modules. Orange circles 
represent the seven modules and selected enriched pathways in each module are listed in the 
orange boxes along with their relative statistical significance (p-value). Colored pie-charts indicate 
the percentage of genes targeted in each module by CTD-2020K17.1 (green); LINC00657 (red) and 
LINC00511 (blue). Colored boxes indicate miRNAs that target genes included in the modules and 
that are targeted by CTD-2020K17.1 (green box), LINC00657 (red box) and LINC00511 (blue box). 
Figure 4. Pathways enrichment of modulated genes included in the modules. Orange circles represent
the seven modules and selected enriched pathways in each module are listed in the orange boxes
along with their relative statistical significance (p-value). Colored pie-charts indicate the percentage of
genes targeted in each module by CTD-2020K17.1 (green); LINC00657 (red) and LINC00511 (blue).
Colored boxes indicate miRNAs that target genes included in the modules and that are targeted by
CTD-2020K17.1 (green box), LINC00657 (red box) and LINC00511 (blue box).
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M5 included 74 genes and was targeted by 49 miRNAs. Pathways related to apoptosis were
the most enriched in module M5, aside from the “Antigen Presentation” pathway. Other important
pathways highly enriched in this module also included “Class I PI3K signaling events mediated by
Akt”, “EGF receptor (ErbB1) signaling pathway”, mTOR signaling pathway” and “GMCSF-mediated
signaling events”.
M6 included five genes and was targeted by 10 miRNAs. We did not observe any statistical
enrichment in Module M6, which was probably due to the small number of genes that composed
this cluster.
Finally, M7 included 28 genes and was targeted by 20 miRNAs. “Cytokine Signaling in Immune
system”, “TCR signaling in naive CD8+ T cells” and “Immune System” were the most enriched signaling
pathways in Module M7. Additional notable pathways enriched in this module were “Signaling
by Interleukins”, “GMCSF-mediated signaling events”, “CXCR4-mediated signaling events”, “EGF
receptor (ErbB1) signaling pathway”, “Class I PI3K signaling events mediated by Akt”, “Signaling
events mediated by Hepatocyte Growth Factor Receptor (c-Met)”, “IFN-gamma pathway” and
“Interferon alpha/beta signaling”.
When we performed a pathway enrichment analysis on the genes targeted within the 7 modules,
we found that most of the pathways enriched in the modules also were enriched in the genes targeted
in the whole transcriptome. This finding suggests that regulation of highly interactive genes associated
with the modules may have a prominent role in the pSjS transcriptome.
4. Discussion
Sjögren’s syndrome is a chronic autoimmune disorder, primarily affecting exocrine glands, and is
of unknown origin. The interplay among genetic background, environmental factors, mainly infectious
agents, and epigenetics, however, play a pivotal role on the pathogenesis of the disease.
Long non-coding RNAs (lncRNAs) exert a control on gene expression at multiple levels and
recently have emerged as crucial components of the epigenetic machinery. Moreover, a growing
body of evidence has highlighted the involvement of lncRNAs in different types of autoimmune
diseases [47,48].
Several disturbed epigenetic mechanisms, including DNA demethylation, microRNAs modulation
and aberrant chromatin positioning have been described in pSjS [49]; however, very little is known of
the potential role played by lncRNAs in pSjS. Particularly, a detailed analysis of functional interactions
among lncRNA and the pSjS transcriptome has not been attempted yet. During this study we have,
therefore, inspected crucial molecular interactions among modulated genes and lncRNAs in pSjS,
interactions that may be of relevance in the pathogenesis of the disease.
The expression profiles of a vast number of coding and non-coding genes have been analysed at
the same time and, by a multiple step process, modulated lncRNAs that possibly were connected to
the pSjS transcriptome were selected.
A sophisticated network analysis was carried out on the entire set of molecular interactions among
modulated genes and lncRNAs, thus outlining reliable lncRNA–miRNA–gene functional interactions.
Through a complex network analysis of the whole set of molecular interactions among modulated
genes and lncRNAs, we further selected those lncRNAs that targeted modules of the most highly
connected genes in the pSjS interactome, since they may have a major impact on pSjS gene modulation.
Using this procedure, we chose lncRNAs on the basis of their connectivity (highly versus poorly
connected lncRNAs).
Using this approach, we identified three lncRNAs, namely LINC00657, LINC00511 and
CTD-2020K17.1, characterized by a high degree of connectivity. Considering this, LINC00657 could
exert a prominent role in pSjS gene modulation since it targeted the highest number of highly connected
transcripts and, therefore, regulated the vast majority of the disease-related pathways.
Noteworthy, many of the miRNAs targeted by these three lncRNA, which modulate highly
connected genes, have been already associated to pSjS.
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Several targeted genes with a high degree of connectivity were involved in inflammation, such as
the IL-6 receptor (IL6R) and the enhancer of IL-6 production (CEBPD) or in the immune response, such
GATA3, that is crucial for T cell development, and the three type I interferon-responsive-genes IRF5,
IRF9 and KLHL20.
Genes modulated during type I interferon pathway activation (like IRF5 and STAT4) were
associated with risk of pSjS, and a type I interferon signature has been described in pSjS patients.
Moreover, this signature strongly correlates with the presence of anti-SSA/Ro antibodies [50].
Interestingly, the three lncRNAs also targeted highly connected genes involved in B-cell
physiology and malignancy, including IL15 (LINC00657), WDR5 (LINC00657), GNAI2 (LINC00657
and CTD-2020K17.1), LTBR (LINC00511), CBX8 (LINC00657), BAK1 (CTD-202K17.1 and LINC00511),
BAX (LINC00511), ENO1 (LINC00657), HNRNPL (CTD-2020K17.1), and TRAF3 (LINC00657 and
CTD-2020K17.1).
The involvement of B cells in the pSjS pathogenesis has been documented well and an increased
number of mature B cells have been found in patients with pSjS [51]; interestingly, IL15 and WDR5
play a crucial role in both B cell proliferation and differentiation and GNAI2 regulates B cell trafficking
into and within lymph nodes [52]. Moreover, germinal centre (GC)-like structures have been described
within the pSjS salivary gland epithelium [51] and, not surprising, LINC00511 and LINC00657
respectively targeted the modulated genes LTBR and CBX8 that are involved on GC formation in
inflamed tissues [53,54]. Worth mentioning, three patients presented germinal centre-like structures in
their labial salivary gland biopsy.
It has been observed that pSjS patients have an increased risk to develop B cell lymphoproliferative
disorders [55] and, noteworthy, BAK1 and BAX are overexpressed in diffuse large B cell lymphoma [56];
ENO1 promotes tumor proliferation in Non-Hodgkin’s Lymphomas and stimulates immunoglobulin
production [57]; hnRNPL induces BCL2 overexpression in many B cell lymphomas [58] whereas TRAF3
is a tumor suppressor gene in B lymphocytes and frequently is inactivated in human B lymphoma
and multiple myeloma [59]. Interestingly, we found that TRAF3 resulted in down-modulation in our
patients with pSjS.
We also observed that several miRNAs targeted by the three lncRNAs that modulated highly
connected genes have a documented role in B cell development and in B cell lymphomagenesis. It is
worthwhile mentioning that one of the patients developed a B cell lymphoma soon after enrollment in
the study.
It has been long recognised that disorders can be viewed in the context of signaling pathway
deregulation. We therefore inspected all the signaling pathways that were enriched in modulated genes
targeted by the three selected lncRNAs and we discovered that they regulate well-known signaling
networks. Moreover, we observed that the vast majority of these pathways also were enriched in all
the seven targeted gene modules, thus indicating that the three lncRNAs targeted pathways closely
related to the disease pathogenesis.
The selected lncRNAs targeted pathways involved in the development of lacrimal and salivary
glands including those of Syndecan (LINC00657, LINC00511 and CTD-2020K17.1), Wnt (LINC00511),
TGF-beta receptor (LINC00657 and LINC00511), BMP receptor (CTD-2020K17.1), SMAD proteins
(LINC00657 and LINC00511), EGF receptor (LINC00657, LINC00511 and CTD-2020K17.1) and HGF
receptor (LINC00657, LINC00511 and CTD-2020K17.1).
The development of both salivary and lacrimal glands is a finely tuned process defined as
“branching morphogenesis” that relies on the differential expression of cellular surface receptors and
extracellular matrix components like proteoglycans. Indeed, the interactions between cell receptors
and ECM elements boost the activation of downstream intracellular signaling pathways that induce
the differentiation of progenitor cells into acinar lobules and ducts [60].
Among these pathways, the Wnt signaling is involved in distinct space and temporal patterns
during salivary gland development [61] and, interestingly, hypermethylation of this pathway has been
observed in salivary gland epithelial cells from patients with Sjögren’s syndrome [62].
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TGF-beta also can control salivary gland development by modulating cellular growth and
differentiation, moreover, it alters salivary gland physiology by regulating angiogenesis and
inflammation [63]. Noteworthy, it has been observed that deletion of TGF-beta signaling in mice
salivary glands induces a Sjögren’s syndrome-like autoimmune disorder [63].
The Smad and BMP proteins are downstream mediators of the TGF-beta signaling and
influence branching morphogenesis of both lacrimal and salivary glands by promoting mesenchymal
proliferation [64,65]. Interestingly, through Smad proteins, TGF-beta also stimulates transcription and
subsequent IgA isotype expression in B lymphocytes [66].
Another signaling pathway involved in salivary gland morphogenesis is that of EGF [67], a
molecule that also is secreted by lacrimal glands and represents one of the most abundant growth
factors in human tears [68]. Particularly, this cytokine can boost migration and proliferation of corneal
epithelial cells during wound healing [68].
HGF plays a crucial role in salivary gland development [69] and modulates cell behaviour in
acinar and ductal epithelial cells of lacrimal glands [70].
It is well known that the structural and morphological integrity of cell aggregates is pivotal to
maintain epithelial functional homeostasis and one of the crucial events involved in the development
of autoimmunity is the loss of the mucosal barrier integrity, as in the case of Sjögren’s syndrome, where
the protective function of glandular epithelia is compromised [71].
Interestingly, we observed that the three selected lncRNAs target molecular pathways that regulate
cell adhesion, for example those of integrins (LINC00657 and LINC00511), E-cadherins (LINC00657
and LINC00511), Nectins (LINC00657, LINC00511 and CTD-2020K17.1), CDC42 (LINC00657 and
LINC00511) and focal adhesion kinases (LINC00657, LINC00511 and CTD-2020K17.1).
Marked alteration of integrin expression has been described in pSjS salivary glands [72] and it
has been related to the observed detachment of glandular acinar cells. Moreover, elevated serum
levels of the soluble form of the adherens junction-associated proteins, E-cadherins, were detected in
pSjS patients and it has been related to tissue regeneration induced by chronic inflammation in pSjS
glandular epithelia [71]. Additionally, E-cadherins also play a pivotal role in the adhesive interactions
between epithelial cells and intraepithelial lymphocytes [73].
To form adherens junctions, E-cadherins associate to the nectin proteins that also are involved in
the formation of tight junctions [74]. Specifically, nectins induce activation of Cdc42-mediated signaling,
regulating cell polarization and, noteworthy, it has been observed that the secretory dysfunction in
pSjS patients also is due to the impairment of epithelial cell polarity [75].
The Cdc42 molecules, in turn, also modulate the activation state of the focal adhesion kinase
proteins, another junctional system deregulated in pSjS [71].
Severe disaggregation of the basal lamina associated to the glandular epithelium has been
described in pSjS and this event allows inflammatory cells and cytotoxic T lymphocytes to infiltrate
acini and ducts [76]. Proteoglycans are a key component of the basal lamina structure and, interestingly,
all three lncRNAs targeted proteoglycans, signaling suggesting that they may also be involved in the
basal lamina modification, a key feature in pSjS pathogenesis.
Aside from the above mentioned histopathological changes, apoptosis also is involved in
pSjS-associated glandular damage, and both apoptotic cells and expression of the apoptosis-regulating
proteins have been detected in salivary glands from pSjS patients in many studies [77]. Particularly, it
has been suggested that apoptosis might be the initial trigger for autoimmunity in this disease [76]
and, noteworthy, proapoptotic signaling pathways also were targeted by the selected lncRNAs.
Leukocyte infiltration in the damaged pSjS glandular epithelium enhances the inflammatory
environment that also is sustained by epithelial cell production of adhesion molecules and
chemokines [78]. Several proinflammatory pathways were targeted by the selected lncRNAs,
including signaling by TNF/NF-Kb (LINC00657), p38 MAP kinase (CTD-2020K17.1), IFN-gamma
(LINC00657, LINC00511 and CTD-2020K17.1), GMCSF (LINC00657, LINC00511 and CTD-2020K17.1)
and IL-8 (LINC00657).
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Tumor Necrosis Factor (TNF) is a strong inducer of NF-kappa B transcription [79] that has
been implicated in the development of several autoimmune diseases, and correlates to the chronic
inflammation that characterizes pSjS [80]. Moreover, the proinflammatory factor p38 MAP kinase is
thought to be involved in the pathogenesis of pSjS [81]. Sphingosine-1-phosphate regulates T cell
development and tissue-homing patterns and plays an important role in the local immune responses
in pSjS glandular tissue [82]. Moreover, together with IFN-gamma, this molecule is thought to increase
IL-6 secretion by pSjS salivary glands [82].
IFN-γ is crucial for T cell differentiation and immunoglobulin class switching in B cells and plays
an important role in macrophage activation, inflammation and tissue damage [83]. Moreover, this
molecule has been implicated in the development of autoimmunity as well as being associated with
more severe forms of pSjS [84].
The immune system has a crucial role in the tissue damage observed in pSjS and both innate and
adaptive immunity strongly contribute to this event. Specifically, it has been described that the type-I
interferon (IFN-I) signature is involved crucially in the disease pathogenesis [85] and, interestingly, the
selected lncRNAs targeted gene modules involved in IFN-I signaling, moreover, they also targeted
molecular pathways of the T cell-associated immune response (i.e., TCR and calcineurin-dependent
NFAT signaling).
It has been observed that T cells represent the majority of lymphocytes infiltrating the pSjS salivary
glands and pro-inflammatory Th1 cell cytokines are increased in saliva of patients with pSjS [86].
Additionally, the presence of regulatory T cells (Treg) also have been identified in pSjS salivary glands
and their increased presence is related strongly to a high rate of inflammation in tissue lesions [86].
Noteworthy, the calcineurin-dependent NFAT signaling plays a pivotal role for both development and
functions of these cells [87].
There is a body of evidence also supporting the involvement of B cells in pSjS pathogenesis and,
indeed, pSjS patients clearly manifest clinical signs of B cell activation [51]. Furthermore, B cells have
been identified in the pSjS salivary glands where they can form ectopic germinal centres [51]. As we
previously mentioned, we describe that selected lncRNAs can modulate miRNAs involved in B cell
development and, interestingly, we also observed that they targeted signaling pathways involved in B
cell differentiation and functions such as CXCR4 (LINC00657 and LINC00511) signaling, Class I PI3K
and mTor pathways (LINC00657, LINC00511 and CTD-2020K17.1).
Class I PI3K is expressed predominantly by B cells and its signaling pathway is activated promptly
upon B cell receptor engagement [88]. Moreover, inhibition of this pathway strongly interferes with
pre-B-cell expansion [89]. The PI3k signaling also activates the Akt and mTor pathways which also
are involved in B cell proliferation [88] and, noteworthy, their activation has been observed in B cell
lymphomas [88]. Finally, an important role for CXCR4 in regulating B cell homeostasis of humoral
immunity has been described [90] and noteworthy, a significantly higher expression of both surface
CXCR4 and CXCR4 messenger RNA (mRNA) has been reported in peripheral blood B cells from
patients with pSjS [91].
We are aware of the limitations of gene expression and microarray analyses, limitations both
at preanalytical and analytical levels. Thus, the first, and most important, aspect at a preanalytical
level is the correct stratification of the patients and the identification of subjects at the same stage
of disease and with similar clinical features. Another important aspect is that the analysis reflects a
particular moment in the course of the disease. The method we are reporting here, however, is the
most informative for a global evaluation of gene expression, microRNA and lncRNA and, therefore, for
the understanding of the genetic and epigenetic processes that play a pivotal role in the pathogenesis
of immune-mediated diseases.
5. Conclusions
To conclude, this is the first report that functionally correlates lnc-RNAs modulation to gene
expression profiles of pSjS patients. Indeed, the described lncRNAs target gene pathways that are
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involved in important features of the disease, including epithelial cell damage, autoimmunity and B
cell hyperactivation. Furthermore, the selected lncRNAs regulate B cell lymphomagenesis-associated
microRNAs, thus suggesting their possible involvement in the increased risk to develop lymphoma
that is observed in pSjS patients.
Taken together, our findings add new pieces of evidence on the importance of epigenetics in
the pathogenesis of pSjS and may open promising avenues for novel therapeutic approaches to the
treatment of the disease.
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